EP1220606A1 - Methodes de production d'une molecule cible chez un animal transgenique et de purification de la molecule cible - Google Patents
Methodes de production d'une molecule cible chez un animal transgenique et de purification de la molecule cibleInfo
- Publication number
- EP1220606A1 EP1220606A1 EP00970945A EP00970945A EP1220606A1 EP 1220606 A1 EP1220606 A1 EP 1220606A1 EP 00970945 A EP00970945 A EP 00970945A EP 00970945 A EP00970945 A EP 00970945A EP 1220606 A1 EP1220606 A1 EP 1220606A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- matrix
- target
- multivalent
- transgenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 147
- 238000000034 method Methods 0.000 title claims abstract description 87
- 238000000746 purification Methods 0.000 title claims abstract description 20
- 241001465754 Metazoa Species 0.000 title claims description 113
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 426
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 416
- 229920001184 polypeptide Polymers 0.000 claims abstract description 415
- 239000011159 matrix material Substances 0.000 claims abstract description 93
- 235000013336 milk Nutrition 0.000 claims description 100
- 239000008267 milk Substances 0.000 claims description 100
- 210000004080 milk Anatomy 0.000 claims description 100
- 230000014509 gene expression Effects 0.000 claims description 47
- 230000003197 catalytic effect Effects 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 210000002919 epithelial cell Anatomy 0.000 claims description 21
- 239000001913 cellulose Substances 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 239000011541 reaction mixture Substances 0.000 claims description 10
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- 238000012250 transgenic expression Methods 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 description 142
- 102000004169 proteins and genes Human genes 0.000 description 123
- 235000018102 proteins Nutrition 0.000 description 117
- 210000001519 tissue Anatomy 0.000 description 71
- 239000003446 ligand Substances 0.000 description 43
- 108010076119 Caseins Proteins 0.000 description 36
- 102000011632 Caseins Human genes 0.000 description 34
- 238000003776 cleavage reaction Methods 0.000 description 32
- 239000000203 mixture Substances 0.000 description 31
- 230000007017 scission Effects 0.000 description 31
- 241000124008 Mammalia Species 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 29
- -1 e.g. Substances 0.000 description 28
- 150000001413 amino acids Chemical class 0.000 description 24
- 239000012530 fluid Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 description 18
- 241000283707 Capra Species 0.000 description 15
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 14
- 235000021240 caseins Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000012212 insulator Substances 0.000 description 14
- 102000014914 Carrier Proteins Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 13
- 108091008324 binding proteins Proteins 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000005018 casein Substances 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 13
- 241000283690 Bos taurus Species 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 102000004407 Lactalbumin Human genes 0.000 description 12
- 108090000942 Lactalbumin Proteins 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 108091005804 Peptidases Proteins 0.000 description 11
- 102000035195 Peptidases Human genes 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 102000008192 Lactoglobulins Human genes 0.000 description 10
- 108010060630 Lactoglobulins Proteins 0.000 description 10
- 239000004365 Protease Substances 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 9
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 239000005862 Whey Substances 0.000 description 9
- 102000007544 Whey Proteins Human genes 0.000 description 9
- 108010046377 Whey Proteins Proteins 0.000 description 9
- 210000005075 mammary gland Anatomy 0.000 description 9
- 235000019419 proteases Nutrition 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 235000021247 β-casein Nutrition 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 108091036066 Three prime untranslated region Proteins 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 235000002198 Annona diversifolia Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108090000746 Chymosin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 108010011756 Milk Proteins Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 108700023418 Amidases Proteins 0.000 description 3
- 102000004411 Antithrombin III Human genes 0.000 description 3
- 108090000935 Antithrombin III Proteins 0.000 description 3
- 241000282836 Camelus dromedarius Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 241000282842 Lama glama Species 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 102000005922 amidase Human genes 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 229960005348 antithrombin iii Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229940080701 chymosin Drugs 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100022987 Angiogenin Human genes 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010017544 Glucosylceramidase Proteins 0.000 description 2
- 102000004547 Glucosylceramidase Human genes 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 108091060545 Nonsense suppressor Proteins 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 229940021722 caseins Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940012426 factor x Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000012451 transgenic animal system Methods 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 235000021241 α-lactalbumin Nutrition 0.000 description 2
- 235000021246 κ-casein Nutrition 0.000 description 2
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 101000741059 Bos taurus Alpha-S2-casein Proteins 0.000 description 1
- 101000946377 Bos taurus Alpha-lactalbumin Proteins 0.000 description 1
- 101000741065 Bos taurus Beta-casein Proteins 0.000 description 1
- 101001008231 Bos taurus Beta-lactoglobulin Proteins 0.000 description 1
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 101710100588 Erythroid transcription factor Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000001133 Fertilins Human genes 0.000 description 1
- 108010069446 Fertilins Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101001035782 Gallus gallus Hemoglobin subunit beta Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 description 1
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 description 1
- 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 description 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 1
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100518987 Mus musculus Pax1 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- 101001050287 Mus musculus Transcription factor Jun Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100032970 Myogenin Human genes 0.000 description 1
- 108010056785 Myogenin Proteins 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 description 1
- 101000895752 Rattus norvegicus Alpha-S2-casein-like A Proteins 0.000 description 1
- 101000947125 Rattus norvegicus Beta-casein Proteins 0.000 description 1
- 101000667278 Rattus norvegicus Whey acidic protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 101001000154 Schistosoma mansoni Phosphoglycerate kinase Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101710185500 Small t antigen Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101710143177 Synaptonemal complex protein 1 Proteins 0.000 description 1
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 108700020987 Wnt-1 Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 108700005856 engrailed 2 Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000017730 intein-mediated protein splicing Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000023247 mammary gland development Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011824 transgenic rat model Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Definitions
- U.S. Patent Number 5,639,640 discloses recombinant expression of human follicle stimulating hormone (FSH) in mammalian cell culture.
- FSH human follicle stimulating hormone
- Such mammalian cell culture fermentation systems are extremely expensive to operate, and the polypeptides thereby produced are part of a complex mixture of proteins present in the growth medium.
- Efforts to overcome the problems present in these systems resulted in transgenic expression of recombinant polypeptides in various transgenic animal systems. This effort has allowed the high level transgenic expression of polypeptides, thereby eliminating the need for the expensive mammalian cell culture fermentation systems for production of recombinant polypeptides.
- polypeptides thereby produced remain a substituent of a complex mixture of milk proteins and methods are need to purify the polypeptides from such mixture.
- the present invention features methods of producing target molecules in transgenic animals and methods of purifying such target molecules.
- the target molecule is preferably a target polypeptide.
- the invention is based, in part, on the discovery that a target polypeptide can be expressed and secreted in an inactive form into the milk of a transgenic animal and then activated. This can allow for avoidance of complications that can arise by producing the protein in active form in the animal. For example, production of certain proteins including enzymes, growth factors, hormones and cytokines, in the milk of a transgenic animal has been found to cause health problems in the animal. Methods of the invention can minimize such problems.
- the invention also features systems and methods for the purification of these and other target molecules present in biological systems such as milk.
- transgenic expression of multivalent binding polypeptides such as affinity ligands
- the transgenic multivalent binding polypeptides can bind both a target molecule and a preselected ligand, e.g., a preselected ligand of a phase separable matrix.
- the invention features, a method of producing a target polypeptide in a transgenic animal.
- the method includes: producing the polypeptide in an inactive state; obtaining the inactive polypeptide; and activating the polypeptide, to thereby provide the target polypeptide.
- the polypeptide is produced in an inactive state in a tissue or product, e.g., a fluid of the transgenic animal, such as milk.
- a tissue or product, e.g., milk, containing inactive protein is obtained from the transgenic animal
- the target polypeptide is inactivated by co-expression of the target polypeptide with a binding polypeptide which binds to and inactivates the target polypeptide.
- the binding polypeptide and the target polypeptide exist as a complex in the tissue or product, e.g., fluid, e.g., milk.
- the target polypeptide and binding polypeptide are a ligand and counterligand, e.g., the binding polypeptide is a receptor or ligand, or a fragment of either.
- the binding polypeptide is an antibody or fragment thereof.
- the nucleic acid encoding the target polypeptide is under the control of a tissue specific promoter, e.g., a promoter which directs expression in mammary epithelial cells.
- the nucleic acid encoding the binding polypeptide is under the control of a tissue specific promoter, e.g., a promoter which directs expression in mammary epithelial cells.
- both the nucleic acid encoding the target polypeptide and the nucleic acid encoding the binding polypeptide are under control of the same-type of promoter, e.g., the same type of tissue specific promoter.
- both can be under the control of a promoter which directs expression in mammary epithelial cells, e.g., both can be under control of the same or a different milk specific promoter.
- the milk specific promoter can be, e.g., a casein, a lactoglobulin, a lactalbumin or a whey acid protein (WAP) promoter.
- the nucleic acid which encodes the binding polypeptide also encodes a sequence which encodes at least one amino acid exogenous to the binding polj ⁇ eptide.
- the nucleic acid can further include an amino acid useful in the purification of the binding polypeptide.
- at least one amino acid exogenous to the binding polypeptide can be added, e.g., an added amino acid or amino acids that can bind to a preselected ligand, e.g., a ligand used for purification of the binding polypeptide, e.g., a 6X HIS ligand, a cellulose binding domain (CBD) ligand, a maltose binding protein (MBP) ligand.
- This amino acid (or amino acids) which can bind to a preselected ligand is also referred to herein as a binding moiety, e.g., a binding moiety capable of binding a preselected ligand or matrix.
- the method further includes separating the inactive polypeptide from the tissue or product, e.g., a fluid, e.g., milk, prior to activation.
- the inactive polypeptide is separated from a fluid, e.g., milk, by binding the binding moiety of the binding polj ⁇ eptide/ target polypeptide complex to a preselected ligand, e.g., a 6X HIS ligand (e.g., a metal chelating column), CBD ligand (e.g., cellulose) or a MBP ligand (e.g., maltose).
- a preselected ligand e.g., a 6X HIS ligand (e.g., a metal chelating column), CBD ligand (e.g., cellulose) or a MBP ligand (e.g., maltose).
- the target polypeptide is inactivated by modification of a site needed to activate the polypeptide, e.g., modification of a cleavage site.
- the cleavage site can be, for example, a cleavage site which allows removal of a portion of the polypeptide, e.g., a site which allows for a removal of a pre and/or pro region of the polypeptide.
- the cleavage site is modified such that it is no longer recognized by a processing enzyme, e.g., an endogenous processing enzyme which naturally occurs in the tissue or product.
- the target polypeptide inactivated by modification of a site can further include an additional site which allows activation, e.g., which allows cleavage such as cleavage of a pre and/or pro- region of a polypeptide.
- an endogenous site for proteolytic cleavage can be inactivated and a new site supplied.
- the new site can be supplied by modifying the endogenous cleavage site and/or by adding an additional amino acid or amino acids.
- the new site is not cleaved by any endogenous processing enzyme which naturally occurs in the tissue or product.
- a site cleaved by a protease present in the milk of the transgenic animal can be modified, and a site which can be cleaved by contact with an exogenous chemical or enzyme can be added to the polypeptide.
- the exogenous chemical is: an acid, e.g., cyanogen bromide.
- the exogenous enzyme is an exogenous protease, e.g., chymosin.
- the additional site is cleaved such that the target polypeptide does not include any extraneous sequence. In another preferred embodiment, the site is cleaved such that the target polypeptide includes less than 20, 10, 5, 4, 3, 2, or 1 extraneous amino acid residues.
- the target polypeptide is a human polypeptide.
- the polypeptide is: a hormone, a growth factor, a cytokine.
- the polypeptide is: bone matrix protein (BMP), e.g., BMP-2; erythropoietin; insulin; human growth factor; transforming growth factor- ⁇ .
- BMP bone matrix protein
- the transgenic animal is a mammal, e.g., a goat, cow sheep, rabbit, pig, horse, camel, llama, mouse or rat.
- the invention features, a method for the transgenic production of a target polypeptide.
- the method includes: providing a transgenic animal having a nucleic acid which encodes a target polypeptide under the control of a tissue specific promoter, e.g., a promoter which directs expression in mammary epithelial cells, and a nucleic acid which encodes a polypeptide which binds to the target polypeptide and which is under the control of a tissue- specific promoter, e.g., a promoter which directs expression in mammary epithelial cells; allowing the target polypeptide and the binding polypeptide to be expressed in a tissue or product of the transgenic animal, e.g., the milk of the transgenic animal; separating the target polypeptide from the binding polypeptide, to thereby provide the target polypeptide.
- a tissue specific promoter e.g., a promoter which directs expression in mammary epithelial cells
- a tissue-specific promoter
- the target polypeptide and binding polypeptide are a ligand and counterligand, e.g., the binding polypeptide is a receptor or ligand, or a fragment of either.
- the bmding polypeptide is an antibody of fragment thereof.
- the nucleic acid which encodes the binding polypeptide also encodes a sequence which encodes at least one amino acid exogenous to the binding polypeptide.
- the nucleic acid can further include an amino acid useful in the purification of the binding polypeptide.
- at least one amino acid exogenous to the binding polypeptide can be added, e.g., an added amino acid or amino acids that can bind to a preselected ligand, e.g., a ligand used for purification of the binding polypeptide, e.g., a 6X HIS ligand, a cellulose binding domain (CBD) ligand, a maltose binding protein (MBP) ligand.
- This amino acid (or amino acids) which can bind to a preselected ligand is also referred to herein as a binding moiety, e.g., a binding moiety capable of binding a preselected ligand or matrix.
- the bmding polypeptide and target polypeptide exists as a complex in the tissue, for example, the milk of the transgenic animal.
- the method further includes separating the inactive target polypeptide from the tissue or product, e.g., a fluid, e.g., milk, prior to activation.
- the inactive polypeptide is separated from a fluid, e.g., milk, by binding the bmding moiety of the binding polypeptide/target polypeptide complex to a preselected ligand, e.g., a 6X HIS ligand (e.g., a metal chelating column), CBD ligand (e.g., cellulose) or a MBP ligand (e.g., maltose).
- a preselected ligand e.g., a 6X HIS ligand (e.g., a metal chelating column), CBD ligand (e.g., cellulose) or a MBP ligand (e.g., maltose).
- the promoter which directs expression in mammary epithelial cells is: a casein promoter, e.g., a beta casein promoter; a lactoglobulin promoter, e.g., a beta lactoglobin promoter; a whey acid protein promoter; a lactoalbumin promoter.
- the binding polj ⁇ eptide and the target polypeptide are under the control of the same-type of tissue specific promoter, e.g., both are under the control of a promoter which directs expression in mammary epithelial cells, e.g., both are under the control of the same or different milk specific promoters.
- the transgenic animal is a non-human mammal.
- the mammal is: a goat; a cow; a sheep; a rabbit; a pig; a horse; a llama; a camel; a mouse; a rat.
- the invention features a transgenic system for obtaining, e.g., purifying, a target polypeptide.
- the system includes an animal, e.g., a mammal, which expresses a transgenic multivalent binding polypeptide.
- the multivalent binding polypeptide includes a first binding moiety which binds the target polypeptide and a second bmding moiety which binds a preselected ligand, e.g., a preselected ligand of a matrix.
- the transgenic mammal expresses a transgenic multivalent binding polypeptide in a tissue-specific manner, e.g., the transgenic mammal expresses the multivalent binding polypeptide in a tissue or product, e.g., a fluid (e.g., milk, urine or blood).
- a tissue or product e.g., a fluid (e.g., milk, urine or blood).
- the mammal expresses the transgenic multivalent polypeptide in milk and the nucleic acid encoding the multivalent binding polypeptide is under control of a promoter which directs expression in mammary epithelial cells, e.g., a casein, a lactoglobulin, a lactalbumin or a whey acid protein (WAP) promoter.
- WAP whey acid protein
- the transgenic mammal is a goat, cow, sheep, rabbit, pig, horse, camel, llama, mouse or rat.
- the multivalent binding polypeptide is expressed at high levels in the product, e.g., the fluid, e.g., at least 0.1, 1, 5, 10 mg/ml.
- system further includes a matrix to which the second binding moiety of the multivalent binding polypeptide can bind.
- the target polj ⁇ eptide includes a bindable epitope, e.g., an epitope which is bound by the first binding moiety of the multivalent binding polypeptide.
- the bindable epitope is removable, e.g., the bindable epitope can be removed, e.g., cleaved, from the remainder of the target polypeptide.
- the bindable epitope can be removed by a catalytic moiety.
- the catalytic moiety is part of a second multivalent binding polypeptide, e.g., a second transgenically produced multivalent binding polypeptide.
- the second multivalent binding polypeptide e.g., the second transgenically produced multivalent binding polypeptide
- the second multivalent binding polypeptide includes a first catalytic domain and a second binding moiety which specifically binds a preselected ligand, e.g., a preselected ligand of a matrix, e.g., a matrix which is different than the matrix specifically bound by the second bmding moiety of the first transgenic multivalent binding polypeptide.
- both the target polypeptide and the multivalent binding polypeptide are expressed transgenically into milk.
- the target polypeptide and the multivalent polypeptide can be expressed by separate animals or by the same animal.
- the target polypeptide and the first and second multivalent polypeptides are transgenically expressed in milk. All of these polypeptides can be expressed by different animals or two or more can be produced by the same animal.
- the invention features a method for obtaining, e.g., purifying, a target polypeptide from a biological system.
- the target polypeptide includes a bindable epitope.
- the method includes: contacting a composition which includes a target polypeptide from a biological system with a transgenically expressed multivalent binding polypeptide to form a reaction mixture, to thereby obtain the target polypeptide from the biological system.
- the multivalent binding polypeptide includes a first binding moiety which binds the target molecule, e.g., binds an epitope of the target molecule, and a second binding moiety which binds to a matrix.
- the method further includes: maintaining the mixture of the composition and the multivalent binding polypeptide such that the first binding moiety of the multivalent binding polypeptide can bind the target polypeptide, e.g., the bindable epitope of the target polypeptide.
- the method further includes: contacting the mixture with a matrix to which the second binding moiety of the multivalent binding polypeptide can bind, and allowing the second binding moiety of the multivalent binding polypeptide to bind to the matrix.
- the method further includes: removing any unbound components of the mixture, and obtaining, e.g., eluting, the target polypeptide from the mixture to thereby obtain the target polypeptide.
- the target polypeptide includes a bmdable epitope, e.g., an epitope which is bound by the first binding moiety of the multivalent binding polypeptide.
- the bindable epitope is removable, e.g., the bindable epitope can be removed, e.g., cleaved, from the remainder of the target polypeptide.
- the bindable epitope can be removed by a catalytic moiety.
- the catalytic moiety is part of a second multivalent binding polypeptide, e.g., a second transgenically produced multivalent binding polypeptide.
- the second multivalent binding polypeptide e.g., the second transgenically produced multivalent binding polypeptide
- the second multivalent binding polypeptide includes a first catalytic domain and a second binding moiety which specifically binds a matrix, e.g., a matrix which is different than the matrix specifically bound by the second binding moiety of the first transgenic multivalent binding polypeptide.
- the composition from a biological system can be a product obtained from a transgenic animal, e.g., a transgenic mammal.
- the product can be a fluid, e.g., milk, urine or blood.
- the composition from the biological system is contacted with sample, e.g., a fluid, e.g., milk, urine or blood, containing the transgenic multivalent binding polypeptide.
- sample e.g., a fluid, e.g., milk, urine or blood
- a fluid e.g., milk, urine or blood
- the milk contains high levels of the transgenic multivalent binding protein, e.g., at least 0.1, 1, 5, 10 mg/ml.
- both the target polypeptide and the multivalent binding polypeptide are expressed transgenically into milk.
- the target polypeptide and the multivalent polypeptide can be expressed by separate animals or by the same animal.
- the target polypeptide and the first and second multivalent polypeptides are transgenically expressed in milk. All of these polypeptides can be expressed by different animals or two or more can be produced by the same animal.
- the invention features a multiple animal transgenic system which can be used to express and/or obtain, e.g., purify, a target polypeptide, e.g., a target polypeptide which includes a bmdable epitope.
- a target polypeptide e.g., a target polypeptide which includes a bmdable epitope.
- the system includes a first transgenic animal, e.g., transgenic mammal, which expresses a transgenic multivalent binding polypeptide which includes a first binding moiety which binds the target polypeptide, e.g., binds the bindable epitope of the target polj ⁇ eptide, and a second bmding moiety which binds a matrix.
- the first transgenic animal expresses the multivalent binding polypeptide into a product, e.g., a fluid, e.g., milk, blood, urine.
- the multivalent binding polypeptide is present at high levels in milk of the first transgenic animal, e.g., at levels of at least 0.1, 1, 5, 10 mg/ml.
- the first transgenic animal is a transgenic mammal.
- the transgenic mammal expresses a transgenic multivalent binding polypeptide in a tissue-specific manner, e.g., the transgenic mammal expresses the multivalent binding polypeptide in a fluid, e.g., milk, urine or blood.
- the mammal expresses the transgenic multivalent polypeptide in milk and the DNA sequence encoding the multivalent binding polypeptide is under control of a promoter which directs expression in mammary epithelial cells, e.g., a casein, a lactoglobulin, a lactalbumin or a whey acid protein (WAP) promoter.
- WAP whey acid protein
- the system further includes a second transgenic animal, e.g., transgenic mammal, which expresses a target polypeptide, e.g., a target polypeptide which includes a bindable epitope.
- a target polypeptide e.g., a target polypeptide which includes a bindable epitope.
- the second transgenic animal expresses the target polypeptide into a sample, e.g., a fluid, e.g., milk, blood, urine.
- the target polypeptide is present at high levels in milk of the second animal, e.g., at levels of at least 0.1 , 1, 5, 10 mg/ml.
- the second transgenic animal is a transgenic mammal.
- the second transgenic mammal expresses a target polj ⁇ eptide in a tissue-specific manner, e.g., the transgenic mammal expresses the target polypeptide in a fluid, e.g., milk, urine or blood.
- the mammal expresses the target polj ⁇ eptide in milk and the DNA sequence encoding the target polypeptide is under control of a promoter which directs expression in mammary epithelial cells, e.g., a casein, a lactoglobulin, a lactalbumin or a whey acid protein (WAP) promoter.
- WAP whey acid protein
- the system further includes a matrix to which the second binding moiety of the multivalent binding polypeptide can bind.
- the bindable epitope is removable, e.g., the bindable epitope can be removed, e.g., cleaved, from the remainder of the target polypeptide.
- the bindable epitope can be removed by a catalytic moiety.
- the catalytic moiety is part of a second multivalent binding polypeptide, e.g., a second transgenically produced multivalent binding polypeptide.
- the second multivalent binding polypeptide e.g., the second transgenically produced multivalent binding polypeptide
- the second multivalent binding polypeptide includes a first catalytic domain and a second binding moiety which specifically binds a matrix, e.g., a matrix which is different than the matrix specifically bound by the second binding moiety of the first transgenic multivalent binding polypeptide.
- the second multivalent binding polypeptide can be produced by either: the same transgenic animal which expresses the first multivalent binding polypeptide; the transgenic animal which produces the target polypeptide; or a transgenic animal other than the animal which produces the first multivalent binding polypeptide or the target polypeptide.
- the invention provides a method for expressing and/or obtaining a target polypeptide, e.g., a target polypeptide which includes a bindable epitope, from a product, e.g., a fluid, e.g., milk, blood, urine.
- the method includes: obtaining a product, e.g., a fluid, e.g., milk, which includes a target polj ⁇ eptide from a transgenic animal; and contacting the product, e.g., a fluid, e.g., milk, which includes the target polypeptide, with a transgenic multivalent binding peptide, to form a reaction mixture.
- the multivalent binding polypeptide includes a first binding moiety which can bind the target polypeptide and a second binding moiety which can bind a preselected ligand, e.g., a matrix.
- the method further includes maintaining the mixture of the target polypeptide and the multivalent polypeptide such that the first binding moiety of the multivalent binding polypeptide binds to the target polypeptide, e.g., a bindable epitope of the target polypeptide.
- the method further includes: contacting the mixture with a matrix to which the second binding moiety binds, and allowing the second binding moiety of the multivalent binding polypeptide to bind to the matrix.
- the method can further include removing any unbound components of the mixture, and selectively removing, e.g., eluting, the target polypeptide from the mixture.
- the multivalent binding polypeptide is expressed in the milk of a transgenic animal.
- the multivalent polypeptide is expressed in the milk of the same transgenic animal which expresses the target polj ⁇ eptide or it is expressed in the milk of a different transgenic animal.
- the transgenic multivalent binding polypeptide is present at high levels in milk from the animal, e.g., at levels of at least 0.1, 1, 5, 10 mg/ml.
- the invention features a transgenic animal system used to express and or obtain, e.g., purify, a target polypeptide, e.g., a target polypeptide which includes a bindable epitope.
- the system includes a transgenic animal which expresses in its mammary tissue a transgenic multivalent bmding polypeptide.
- the multivalent binding polypeptide includes a first binding moiety which specifically binds the target polypeptide, e.g., binds a bindable epitope of a target polypeptide, and a second binding moiety which binds a matrix.
- the transgenic animal expresses in its mammary tissue a target polypeptide, e.g., a target polypeptide which includes a bindable epitope.
- a target polypeptide e.g., a target polypeptide which includes a bindable epitope.
- the mammal expresses the transgenic multivalent polypeptide in milk and the DNA sequence encoding the multivalent binding polypeptide is under control of a promoter which directs expression in mammary epithelial cells, e.g., a casein, a lactoglobulin, a lactalbumin or a whey acid protein (WAP) promoter.
- WAP whey acid protein
- the mammal expresses the target polypeptide in milk and the DNA sequence encoding the target polypeptide is under the control of a promoter which directs expression in mammary epithelial cells, e.g., a casein, a lactoglobulin, a lactalbumin or a whey acid protein (WAP) promoter.
- a promoter which directs expression in mammary epithelial cells, e.g., a casein, a lactoglobulin, a lactalbumin or a whey acid protein (WAP) promoter.
- WAP whey acid protein
- the multivalent binding polypeptide is present at high levels in milk of the transgenic animal, e.g., at levels of at least 0.1, 1, 5, 10 mg/ml.
- the target polj ⁇ eptide is present at high levels in milk of the same transgenic animal, e.g., at levels of at least 0.1, 1, 5, 10 mg/ml.
- both the multivalent binding polypeptide and the target molecule are present at high levels, e.g., each are present at levels of at least 0.1, 1, 5, 10 mg/ml.
- the system further includes a matrix to which the second binding moiety specifically binds.
- the bindable epitope of the target polypeptide is removable, e.g., the bindable epitope can be removed, e.g., cleaved, from the remainder of the target polypeptide.
- the bindable epitope can be removed by a catalytic moiety.
- the catalytic moiety is part of a second multivalent binding polypeptide, e.g., a second transgenically produced multivalent binding polypeptide.
- the second multivalent binding polypeptide e.g., the second transgenically produced multivalent binding polypeptide
- the second multivalent binding polypeptide includes a first catalytic domain and a second binding moiety which specifically binds a matrix, e.g., a matrix which is different than the matrix specifically bound by the second binding moiety of the first transgenic multivalent binding polypeptide.
- the second multivalent binding polypeptide can be: expressed by the same tiansgenic animal which expressed the first multivalent binding polypeptide and/or target polypeptide: expressed a transgenic animal other than the transgenic animal which expresses the first multivalent binding polypeptide and/or target polypeptide.
- the invention features a method for expressing and/or obtaining, e.g., purifying, a target polypeptide, e.g., a target polypeptide which includes a bindable epitope.
- the method includes: obtaining milk from a transgenic animal which includes a mixture of a transgenic multivalent binding polypeptide and a target polypeptide, e.g., a target polypeptide which includes a bmdable epitope.
- the multivalent binding polypeptide includes a first binding moiety which can bind the target polypeptide, e.g., a bindable epitope on the target polypeptide, and a second binding moiety which can bind a matrix.
- the method can further include: allowing the first binding moiety of the multivalent binding polypeptide to bind to the target polypeptide, e.g., a bindable epitope of the target polypeptide.
- the method can further include: contacting such mixture with a matrix to which the second binding moiety specifically binds, and allowing the second binding moiety of the multivalent binding peptide to bind to the matrix.
- the method can further include: removing any unbound components of the mixture, and selectively removing, e.g., eluting, the target polj ⁇ eptide from the mixture.
- the multivalent binding polypeptide is present at high levels in milk of the transgenic animal, e.g., at levels of at least 0.1, 1, 5, 10 mg/ml.
- the target polypeptide is present at high levels in milk of the same transgenic animal, e.g., at levels of at least 0.1, 1, 5, 10 mg/ml.
- both the multivalent binding polypeptide and the target molecule are present at high levels, e.g., each are present at levels of at least 0.1, 1, 5, 10 mg/ml.
- systems and methods provide many advantages over previously existing systems.
- the systems and methods according to the invention greatly reduce the time and cost of purifying such biological molecules because they obviate the need to separately purify the affinity ligands and couple them to a functionalized affinity matrix.
- an “epitope”, or a “bindable epitope” is a three- dimensional molecular shape which is specifically bound by a binding moiety.
- a “binding moiety” is a polypeptide portion of a transgenic multivalent binding polypeptide which specifically binds an epitope.
- polypeptide A “polypeptide”, “protein” and “peptide” are used interchangeably herein.
- the polypeptide may be glycosylated or unglycosylated.
- Such polypeptides may include from about three, four, five, six or more amino acids, and may further include secondary, tertiary or quaternary structures, as well as intermolecular associations with other peptides or other non- peptide molecules.
- Such intermolecular associations may be through, without limitation, covalent bonding (e.g., through disulfide linkages), or through chelation, electrostatic interactions, hydrophobic interactions, hydrogen bonding, ion-dipole interactions, dipole-dipole interactions, or any combination of the above.
- a “polypeptide portion” comprises from about 3 to about 100 contiguous and/or noncontiguous amino acids, and can be glycosylated or unglycosylated.
- a "peptide-containing epitope” is an epitope comprised at least in part of an immunological determinant from an amino acid residue of a peptide.
- a "carbohydrate- containing epitope” is an epitope comprised at least in part of an immunological determinant from a carbohydrate portion of a molecule.
- a “lipid-containing epitope” is an epitope comprised at least in part of an immunological determinant from a lipid portion of a molecule.
- immunological determinant is a three-dimensional shape which contributes to the overall three- dimensional shape of an epitope.
- an "immunological determinant from an amino acid residue” is an immunological determinant in which its three-dimensional shape is contributed by all or part of the side-chain and/or alpha-carbon and/or either or both peptide bonds and/or amino and/or carboxy termini of an amino acid residue.
- a “transgenic multivalent binding polypeptide” is a transgenically produced polypeptide which includes a first binding moiety which binds a bindable epitope of a target molecule present in a biological system, and a second binding moiety which binds a matrix.
- a “target molecule” is any molecule which is to be purified. Although the term “target polypeptide” is used throughout the above description of the systems and methods, other target molecules described herein can be used in any of the embodiments.
- a “biological system” includes in vitro cell or tissue extracts, eukaryotic or prokaryotic cell cultures, tissue cultures, organ cultures, living plants and animals, and extracts of living plants or animals.
- a “matrix” is a material which can be phase separated from a biological system.
- Specifically binds means forming a covalent or non-covalent association with an affinity of at least 10 4 M “1 , more preferably 10 6 M “ ', most preferably at least 10 9 M “ ' , under process bmding conditions, e.g., pH 4-9 and ionic strength 50mM to 1 M, which conditions specifically include the conditions present in milk.
- a "removable epitope” is an epitope which can be physically separated from a molecule, preferably by chemical or enzymatic cleavage.
- “High levels” of expression means at least about 0.1 mg/ml, preferably at least about 0.5 mg/ml, and most preferably at least about 1 mg/ml.
- “Selectively eluting” refers to dissociating the target molecule from the transgenic multivalent bmding polypeptide, preferably, without dissociating the transgenic multivalent bmding polypeptide from the matrix.
- a "transgenic animal” is a non-human animal in which one or more, and preferably essentially all, of the cells of the animal contain a heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques known in the art.
- the transgene can be introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus.
- Mammals are defined herein as all animals, excluding humans, which have mammary glands and produce milk.
- a "dairy animal” refers to a milk producing animal.
- the dairy animal produce large volumes of milk and have long lactating periods, e.g., cows or goats.
- the term "plant” refers to either a whole plant, a plant part, a plant cell, or a group of plant cells.
- the class of plants which can be used in the method of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants. It includes plants of a variety of ploidy levels, including polyploid, diploid and haploid.
- target polj ⁇ eptide refers to a polypeptide that is substantially free of cellular material when produced by a cell which expresses the target polypeptide.
- substantially free of cellular material includes preparations of target polypeptide in which the polypeptide is separated from cellular components of the cells in which it is produced.
- the language “substantially free of cellular material” includes preparations of target polypeptide having less than about 30% (by dry weight) of non-target polypeptide (also referred to herein as a "protein impurity” or "contaminating protein”), more preferably less than about 20% of non- target polypeptide, still more preferably less than about 10% of non- target polypeptide, and most preferably less than about 5% non- target polypeptide.
- non-target polypeptide also referred to herein as a "protein impurity” or "contaminating protein”
- Figure 1 depicts an embodiment where the target molecule and the multivalent binding polypeptide are from separate sources.
- Figure 2 depicts an embodiment where the target molecule and the transgenic multivalent binding polypeptide are from the same source.
- Figure 3 depicts an embodiment where a removable epitope of the target molecule is removed by a catalytic moiety of a second multivalent binding polypeptide which also binds a matrix. A different matrix is bound by the second multivalent polypeptide than the target molecule/first multivalent binding polypeptide.
- the invention relates to the transgenic expression and purification of polypeptides from biological systems. More particularly, the invention features transgenic systems for expression and purification of polypeptides, and to methods using such systems.
- the patents and publications cited herein reflect knowledge available to those skilled in the art, and are hereby incorporated by reference in entirety.
- the invention provides systems and methods for the purification of target molecules present in biological systems.
- the systems and methods according to the invention utilize the presence of multivalent binding polypeptides, e.g., transgenically produced multivalent binding polypeptides, as affinity media, to purify such target molecules.
- the multivalent binding polypeptides bind both the target molecule and a matrix, e.g., a phase separable matrix.
- the invention provides systems and methods for both the expression and purification of the target molecules, thereby further simplifying the production process and reducing its cost.
- Both the target polypeptide and the multivalent binding polypeptide can be expressed transgenically, e.g., into animal milk, either in separate animals or the same animal.
- the following methods and systems generally refer to contacting a multivalent binding polypeptide to the matrix and then to the target, the opposite order is equally appropriate for all embodiments.
- the invention provides a transgenic system for purification of a target molecule which includes a bindable epitope.
- the system can include a transgenic animal which expresses, e.g., in mammary tissue, a transgenic multivalent binding polypeptide.
- the multivalent polypeptide includes a first binding moiety which binds to a target polypeptide, e.g., binds to a bindable epitope of a target polypeptide, and a second binding moiety which binds a matrix.
- the system further includes a matrix to which the second binding moiety of the multivalent binding polypeptide specifically binds.
- the transgenic animal can express the multivalent binding polypeptide in a tissue specific manner.
- tissue specific expression can be obtained by having the sequence encoding the target protein under control of a tissue-specific promoter, e.g. a promoter which directs expression in mammary epithelial cells.
- Milk specific promoters can include: casein promoters (e.g., ⁇ -casein, ⁇ -casein, ⁇ -casein or ⁇ -casein promoters); WAP promoters; ⁇ -lactoglobin; and lactalbumin.
- Target molecules can include: nucleic acids, nucleotides, nucleosides, carbohydrates, lipids, hormones, growth factors, enzyme cofactors, other naturally occurring ligands, and polypeptides. Bindable epitopes of the target molecule can include: carbohydrate-containing epitopes, lipid-containing epitopes and peptide-containing epitopes, as well as epitopes comprising any combination of these.
- the target molecule can be an endogenous or an exogenous molecule.
- the invention can also include a multiple animal transgenic system for expression and/or purification of a target polypeptide, e.g., a target polypeptide having a bindable epitope.
- the system can include a first transgenic animal which expresses, e.g., in mammary tissue, a transgenic multivalent binding polypeptide.
- the transgenic multivalent binding polypeptide can include a first binding moiety which specifically binds the target polypeptide, e.g., a bmdable epitope of the target polypeptide, and a second binding moiety which specifically binds a matrix.
- the system can further include a second animal which expresses, e.g., in mammary tissue, a target polypeptide having a bindable epitope.
- the system can further include a matrix to which the second binding moiety specifically binds.
- the second animal can be a transgenic animal which expresses a target polypeptide.
- the second animal can be a transgenic animal which expresses the target polj ⁇ eptide in a tissue specific manner, e.g., it expresses the target polypeptide in its mammary tissue.
- the bindable epitope of a target molecule can be a removable epitope.
- the epitope can be removed by a catalytic moiety of a second multivalent binding polypeptide, e.g., a second transgenically produced multivalent polypeptide.
- a second transgenic multivalent binding polypeptide can include a first catalytic domain and a second binding moiety which specifically binds a matrix.
- the matrix specifically bound by the second binding moiety of the second transgenic multivalent binding polypeptide is different than the matrix specifically bound by the second binding moiety of the first transgenic multivalent binding polypeptide.
- the catalytic domain of a second multivalent binding polypeptide can catalyze the cleavage of the bindable epitope from the removable epitope.
- the catalytic domain can have an amidase activity.
- the invention can also feature a single animal transgenic system for expression and/or purification of a target polypeptide, e.g., a target polypeptide which includes a bindable epitope.
- the system includes: a transgenic animal which expresses, e.g., in mammary tissue, a transgenic multivalent binding polypeptide and expresses, e.g., in mammary tissue, a target polypeptide.
- the multivalent binding polypeptide can include a first binding moiety which binds a bindable epitope of the target polypeptide and a second binding moiety which binds a matrix.
- the multivalent binding polypeptide and the target polypeptide can be expressed in the same or different tissues.
- the target polypeptide encoding sequence can be under the control of a general promoter and the multivalent binding polypeptide encoding sequence can be under the control of a tissue specific promoter, or visa versa;
- the target polypeptide encoding sequence can be under the control of a tissue specific promoter and the multivalent polypeptide encoding sequence can be under the control of a tissue specific promoter for a different tissue- type, e.g., the target polypeptide encoding sequence can be under the control of a urine specific promoter and the multivalent binding polypeptide encoding sequence can be under the control of a milk specific promoter;
- both the multivalent binding polypeptide encoding sequence and the target polypeptide encoding sequence can be under the control of tissue specific promoters for the same tissue type, e.g., the multivalent binding polypeptide encoding sequence can be under control of a milk specific promoter and the target
- the multivalent binding polypeptide and the target polypeptide are expressed in the milk of transgenic animal.
- the transgenic multivalent binding polypeptide is, preferably, present at sufficient levels in the milk to bind at least 5%, 10%, 15%, 20%, 30%, 40%>, 50%, 60%, 70%), 80%, 85%, 90%, 95%, 98%, 99% or all of the target molecule.
- the multivalent binding polypeptide can be present at high levels, e.g., at least 0.1, 1, 5, 10 mg/ml, in milk of the transgenic animal.
- the target polypeptide is, preferably, present at high levels, e.g., at least 0.1, 1, 5, 10 mg/ml, in milk of the same transgenic animal.
- the system can further include a matrix to which the second binding moiety of the multivalent binding polypeptide specifically binds.
- the bindable epitope of a target molecule can be a removable epitope.
- the epitope can be removed by a catalytic moiety of a second multivalent binding polypeptide, e.g., a second transgenically produced multivalent polypeptide.
- a second transgenic multivalent binding polypeptide can include a first catalytic domain and a second binding moiety which specifically binds a matrix.
- the matrix specifically bound by the second binding moiety of the second transgenic multivalent binding polypeptide is different than the matrix specifically bound by the second binding moiety of the first transgenic multivalent binding polypeptide.
- the catalytic domain of a second multivalent binding polypeptide can catalyze the cleavage of the bmdable epitope from the removable epitope.
- the catalytic domain can have an amidase activity.
- the target polypeptide can be expressed in an inactive form in the animal's mammary tissue. This aspect can be particularly advantageous in situations in which it is not desired to have the target polypeptide perform its biological function in the mammary tissue.
- the first binding moiety of the multivalent binding polypeptide can bind the target polypeptide in a manner which prevents it from performing its biological function until it is selectively eluted or the bindable epitope can be a removable epitope in which the target polypeptide is not biologically active until the epitope is removed.
- the binding moiety can remove a removable epitope.
- the invention also features methods for obtaining, e.g., purifying, a target molecule which includes a bindable epitope from a biological system.
- the method can utilize any of the systems described above.
- the method can include: contacting a multivalent binding polypeptide, e.g., any multivalent binding polypeptide described herein, with a composition of matter from a biological system to form a reaction mixture.
- the composition of matter can include a target molecule having a bindable epitope.
- the first binding moiety of the multivalent binding polypeptide can bind the bindable epitope of the target molecule.
- the reaction mixture is maintained such that the first binding moiety of the multivalent bmding polypeptide binds to the bindable epitope of the target molecule.
- the mixture can further be contacted with a matrix to which the second binding moiety binds. In the presence of the matrix, the second bmding moiety of the multivalent binding peptide can bind the matrix, and any unbound components of the mixture can be removed.
- the target molecule can then be obtained, e.g., eluted, from the composition of matter.
- the method can also include providing a sample, e.g., a fluid, e.g., milk, urine, blood, which includes a target molecule.
- the sample can be contacted with a multivalent binding polypeptide described herein, to obtain the target molecule.
- a sample which includes a target polypeptide can be obtained from an animal, e.g., a transgenic animal.
- the sample can be obtained from an animal which expresses the target molecule in its milk, e.g., the sample can be obtained by milking the animal.
- the animal can be any transgenic animal which includes a nucleotide sequence encoding the target polypeptide under the control of a milk specific promoter.
- the invention also features methods of obtaining, e.g., purifying, a target molecule, e.g., a target molecule having a bindable epitope.
- the method can include: providing a fluid, e.g., milk, which includes a target molecule, e.g., a target polypeptide, and a multivalent binding polypeptide, a multivalent binding polypeptide described herein.
- the fluid e.g., milk
- the method further includes contacting the fluid with a matrix to which the second binding moiety binds.
- the second binding moiety of the multivalent binding peptide can bind the matrix, and any unbound components of the mixture can be removed.
- the target molecule can then be obtained, e.g., eluted, from the composition of matter.
- the composition of matter from a biological system is contacted with milk containing sufficient levels of a multivalent binding polypeptide to obtain at least 5%, 10%o, 20%), 30%, 40%), 50%, 60%,, 70%, 80%, 85%, 90%, 95%, 98%, 99% or all of the target molecule from the composition of matter.
- the milk can contain high levels of the transgenic multivalent binding protein due to its expression in mammary tissue and secretion into the milk.
- the transgenic multivalent binding polypeptide is present in milk at levels of at least 0.1, 1, 5, 10 mg/ml.
- Biological systems include, for example, plant, fungi, bacterial and animal products.
- Compositions from biological systems can include: conditioned media, tissue extracts, organs and bodily fluids (e.g., blood, plasma, serum, sweat, saliva, urine, milk, etc.).
- Such plant, fungi, bacterial and animal products may include polypeptides expressed from endogenous or exogenously supplied genes.
- the bindable epitope of a target molecule can be a removable epitope.
- the epitope can be removed by a catalytic moiety of a second multivalent binding polypeptide, e.g., a second transgenically produced multivalent polypeptide.
- a second transgenic multivalent binding polypeptide can include a first catalytic domain and a second binding moiety which specifically binds a matrix.
- the matrix specifically bound by the second binding moiety of the second transgenic multivalent binding polypeptide is different than the matrix specifically bound by the second bmding moiety of the first transgenic multivalent binding polypeptide.
- the catalytic domain of a second multivalent binding polypeptide can catalyze the cleavage of the bindable epitope from the removable epitope.
- the catalytic domain can have an amidase activity.
- the target polypeptide can be obtained from the mixture by removing the epitope from the target molecule.
- the target polypeptide can be expressed in an inactive form in the animal's mammary tissue. This aspect can be particularly advantageous in situations in which it is not desired to have the target polypeptide perform its biological function in the mammary tissue.
- the first binding moiety of the multivalent binding polypeptide can bind the target polypeptide in a manner which prevents it from performing its biological function until it is selectively eluted or the bindable epitope can be a removable epitope in which the target polypeptide is not biologically active until the epitope is removed.
- the binding moiety can remove a removable epitope.
- the multivalent binding polypeptides of the invention include a first binding moiety which can bind to a target molecule, e.g., a bindable epitope of a target molecule.
- Preferred first binding moieties include: an antibody, an Fab or F(ab) 2 fragment thereof, or a polypeptide portion comprising a complementarity determining region of an antibody which specifically binds a bindable epitope of the target molecule, a ligand or receptor which binds a bindable epitope of a target molecule, or any other polypeptide portion which specifically binds a bindable epitope of the target molecule, e.g., a polypeptide selected for binding in, e.g., a phage display or 2 hybrid assay.
- Antibodies or Fragments Thereof include: an antibody, an Fab or F(ab) 2 fragment thereof, or a polypeptide portion comprising a complementarity determining region of an antibody which specifically
- Reichman et al, Nature 332: 323-327 (1988) discloses a human antibody on which rat hypervariable regions have been grafted. Verhoeyen, et al, Science 239: 1534-1536 (1988) teaches grafting of a mouse antigen binding site onto a human antibody.
- the multivalent binding polypeptides of the invention also include a second binding moiety which binds to a matrix.
- Second binding moieties can include, for example, antibodies or antibody derivatives, in which case the matrix comprises the antigen or epitope thereof which is specifically bound by the antibody.
- the interaction between the antibody and antigen must be sufficiently avid to prevent dissociation under conditions which would elute the target molecule.
- second-binding moiety-matrix pairs include, without limitation, polyhistidine-nickel metal chelate (elution with ⁇ 250 mM imidazole or low pH), streptavidin-biotin (elution with 6 M urea, pH 4.0), Flag TM peptide-specific MAb (elution with pH 3.0 or 2-5 mM EDTA), S-peptide-S-protein ribonuclease (elution after self-cleavage), glutathione-S-transferase-glutathione (elution with 5-10 mM reduced glutathione), protein A or synthetic ZZ domain of protein A-IgG (elution at low pH), IgG Fc region-protein A (elution at low pH), maltose-binding domains-cross-linked amylose (elution with 10 mM maltose) and cellulose binding domains (CBD)-cellulose or chitin (elution with water or > 4 M
- the target molecule can be an endogenous molecule, e.g., an endogenous polypeptide or an exogenous molecule, e.g., polypeptide.
- the exogenous polypeptide can be a polypeptide which is naturally expressed in the animal but not in a particular tissue or at lower levels in the tissue which it is being expressed, or the exogenous polypeptide can be a polypeptide which is not expressed in the animal, e.g., the animal is a non-human animal which expresses a human polypeptide.
- the target molecule includes a bindable epitope.
- the bindable epitope can be a removable epitope.
- the removable epitope can be removed after the selective elution of the target molecule.
- Such removable epitopes can be derived from polypeptide portions of proteins which are edited after translation by self-splicing, e.g., the so-called "intein"-containing proteins.
- the removable epitope can be joined to the remainder of the target molecule by a specific protease recognition and cleavage site, provided however that no other such site in the target molecule is accessible to the protease.
- the protease can be attached to the matrix.
- the transgenic multivalent binding polypeptide itself can incorporate the protease activity, either as part of the first binding moiety, or as a separate, flexibly-attached additional binding moiety.
- the protease activity is part of the first binding moiety, it is preferred that it have the ability to bind the bindable epitope under one set of conditions and cleave the bindable epitope under a second, different set of conditions.
- Methods for generating non-human transgenic mammals are known in the art. Such methods can involve introducing DNA constructs into the germ line of a mammal to make a transgenic mammal. For example, one or several copies of the construct may be incorporated into the genome of a mammalian embryo by standard transgenic techniques.
- non-human mammals are ruminants, e.g., cows, sheep, camels or goats. Additional examples of preferred non-human animals include oxen, horses, llamas, pigs, mice and rats.
- the mammal used as the source of cells e.g., genetically engineered cell, will depend on the transgenic mammal to be obtained.
- the genome from a bovine should be used from nuclear transfer with a bovine oocyte.
- Protocols for producing tiansgenic goats are known in the art.
- a transgene can be introduced into the germline of a goat by microinjection as described, for example, in Ebert et al. (1994) Bio/Technology 12:699, or nuclear transfer techniques as described, for example, in PCT Application WO 98/30683.
- a protocol for the production of a transgenic pig can be found in White and Yannoutsos, Current Topics in Complement Research: 64th Forum in Immunology, pp. 88-94; US Patent No. 5,523,226; US Patent No.
- a protocol for the production of a transgenic rat can be found in Bader and Ganten, Clinical and Experimental Pharmacology and Physiology, Supp. 3:S81-S87, 1996.
- a protocol for the production of a transgenic cow can be found in U.S. Patent No: 5,741,957, PCT Application WO 98/30683, and Transgenic Animal Technology, A Handbook, 1994, ed., Carl A. Pinkert, Academic Press, Inc.
- a protocol for the production of a transgenic sheep can be found in PCT Publication WO 97/07669, and Transgenic Animal Technology, A Handbook, 1994, ed., Carl A. Pinkert, Academic Press, Inc.
- Transfected Cell Lines Genetically engineered cells for production of a transgenic mammal by nuclear transfer can be obtained from a cell line into which a nucleic acid of interest, e.g., a nucleic acid which encodes a protein, has been introduced.
- a nucleic acid of interest e.g., a nucleic acid which encodes a protein
- a construct can be introduced into a cell via conventional transformation or transfection techniques.
- transfection and “transformation” include a variety of techniques for introducing a transgenic sequence into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextrane-mediated transfection, lipofection, or electioporation.
- biological vectors e.g., viral vectors can be used as described below. Suitable methods for transforming or tiansfecting host cells can be found in Sambrook et al., Molecular Cloning: A Laboratory Manuel, 2" ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other suitable laboratory manuals.
- the DNA construct can be stably introduced into a donor cell line, e.g., an embryonic cell, e.g., an embryonic somatic cell line, by electioporation using the following protocol: the cells are resuspended in PBS at about 4 x 10 6 cells/ml. Fifty micorgrams of linearized DNA is added to the 0.5 ml cell suspension, and the suspension is placed in a 0.4 cm electrode gap cuvette (Biorad). Electioporation is performed using a Biorad Gene Pulser electroporator with a 330 volt pulse at 25 mA, 1000 microFarad and infinite resistance. If the DNA construct contains a Neomyocin resistance gene for selection, neomyocin resistant clones are selected following incubation with 350 microgram/ml of G418 (GibcoBRL) for 15 days.
- a donor cell line e.g., an embryonic cell, e.g., an embryonic somatic cell line
- the DNA construct can be stably introduced into a donor cell line by lipofection using a protocol such as the following: about 2 x 10 5 cells are plated into a 3.5 cmiameter well and transfected with 2 micrograms of linearized DNA using LipfectAMINETM (GibcoBRL). Forty- eight hours after transfection, the cells are split 1:1000 and 1 :5000 and, if the DNA construct contains a neomyosin resistance gene for selection, G418 is added to a final concentration of 0.35 mg/ml. Neomyocin resistant clones are isolated and expanded for cyropreservation as well as nuclear transfer.
- a protocol such as the following: about 2 x 10 5 cells are plated into a 3.5 cmiameter well and transfected with 2 micrograms of linearized DNA using LipfectAMINETM (GibcoBRL). Forty- eight hours after transfection, the cells are split 1:1000 and 1 :5000 and, if the DNA construct contains a neo
- a protein e.g., a heterologous protein
- a specific tissue or fluid e.g., the milk, blood or urine
- the heterologous protein can be recovered from the tissue or fluid in which it is expressed.
- Methods for producing a heterologous protein under the control of a milk specific promoter are described below.
- tissue-specific promoters, as well as, other regulatory elements e.g., signal sequences and sequence which enhance secretion of non-secreted proteins, are described below.
- Milk Specific Promoters Useful transcriptional promoters are those promoters that are preferentially activated in mammary epithelial cells, including promoters that control the genes encoding milk proteins such as caseins, beta lactoglobulin (Clark et al., (1989) Bio/TechnologyX 487-492), whey acid protein (Gordon et al. (1987) Bio/Technology 5: 1183-1187), and lactalbumin (Soulier et al.,
- Casein promoters may be derived from the alpha, beta, gamma or kappa casein genes of any mammalian species; a preferred promoter is derived from the goat beta casein gene (DiTullio, (1992) Bio/Technology K):74-77).
- Milk-specific protein promoter or the promoters that are specifically activated in mammary tissue can be derived from cDNA or genomic sequences. Preferably, they are genomic in origin.
- DNA sequence information is available for the mammary gland specific genes listed above, in at least one, and often in several organisms. See, e.g., Richards et al., J. Biol. Chem. 256, 526-532 (1981) ( ⁇ -lactalbumin rat); Campbell et al., Nucleic Acids Res. 12, 8685-8697 (1984) (rat WAP); Jones et al., J. Biol. Chem. 260, 7042-7050 (1985) (rat ⁇ -casein); Yu-Lee & Rosen, J. Biol. Chem. 258, 10794-10804 (1983) (rat ⁇ -casein); Hall, Biochem. J.
- signal sequences are milk-specific signal sequences or other signal sequences which result in the secretion of eukaryotic or prokaryotic proteins.
- the signal sequence is selected from milk-specific signal sequences, i.e., it is from a gene which encodes a product secreted into milk.
- the milk-specific signal sequence is related to the milk-specific promoter used in the construct, which are described below.
- the size of the signal sequence is not critical. All that is required is that the sequence be of a sufficient size to effect secretion of the desired recombinant protein, e.g., in the mammary tissue.
- signal sequences from genes coding for caseins e.g., alpha, beta, gamma or kappa caseins, beta lactoglobulin, whey acid protein, and lactalbumin can be used.
- a preferred signal sequence is the goat ⁇ -casein signal sequence.
- Signal sequences from other secreted proteins e.g., proteins secreted by kidney cells, pancreatic cells or liver cells, can also be used.
- the signal sequence results in the secretion of proteins into, for example, urine or blood.
- tissue-specific promoters which provide expression in a particular tissue can be used.
- Tissue specific promoters are promoters which are expressed more strongly in a particular tissue than in others. Tissue specific promoters are often expressed essentially exclusively in the specific tissue. For example, if the altered protein is normally expressed in the liver, a liver- specific promoter can be used. This will be the case when a suppressor tRNA is used to alter serum albumin. In this situation, a transgenic sequence encoding the suppressor tRNA can be under the control of a liver-specific promoter.
- Tissue-specific promoters which can be used include: a neural-specific promoter, e.g., nestin, Wnt-1, Pax-1, Engrailed-1, Engrailed-2, Sonic hedgehog; a liver-specific promoter, e.g., albumin, alpha- 1 antirypsin; a muscle-specific promoter, e.g., myogenin, actin, MyoD, myosin; an oocyte specific promoter, e.g., ZP1, ZP2, ZP3; a testes-specific promoter, e.g., protamin, fertilin, synaptonemal complex protein-1; a blood-specific promoter, e.g., globulin, GATA-1, porphobilinogen deaminase; a lung-specific promoter, e.g., surfactant protein C; a skin- or wool- specific promoter, e.g., keratin, elastin; endothelium-
- general promoters can be used for expression in several tissues.
- Examples of general promoters include ⁇ -actin, ROSA-21, PGK, FOS, c-myc, Jun-A, and Jun-B.
- the DNA constructs used to make a tiansgenic animal can include at least one insulator sequence.
- the terms "insulator”, “insulator sequence” and “insulator element” are used interchangeably herein.
- An insulator element is a control element which insulates the transcription of genes placed within its range of action but which does not perturb gene expression, either negatively or positively.
- an insulator sequence is inserted on either side of the DNA sequence to be transcribed.
- the insulator can be positioned about 200 bp to about 1 kb, 5' from the promoter, and at least about 1 kb to 5 kb from the promoter, at the 3' end of the gene of interest.
- the distance of the insulator sequence from the promoter and the 3' end of the gene of interest can be determined by those skilled in the art, depending on the relative sizes of the gene of interest, the promoter and the enhancer used in the construct.
- more than one insulator sequence can be positioned 5 ' from the promoter or at the 3 ' end of the transgene.
- two or more insulator sequences can be positioned 5' from the promoter.
- the insulator or insulators at the 3 ' end of the transgene can be positioned at the 3 ' end of the gene of interest, or at the 3 'end of a 3' regulatory sequence, e.g., a 3' untranslated region (UTR) or a 3' flanking sequence.
- UTR untranslated region
- a preferred insulator is a DNA segment which encompasses the 5' end of the chicken ⁇ - globin locus and corresponds to the chicken 5' constitutive hypersensitive site as described in PCT Publication 94/23046, the contents of which is incorporated herein by reference.
- a cassette which encodes a heterologous protein can be assembled as a construct which includes a promoter, e.g., a promoter for a specific tissue, e.g., for mammary epithelial cells, e.g., a casein promoter, e.g., a goat beta casein promoter, a milk-specific signal sequence, e.g., a casein signal sequence, e.g., a ⁇ -casein signal sequence, and a DNA encoding the heterologous protein.
- a promoter e.g., a promoter for a specific tissue, e.g., for mammary epithelial cells, e.g., a casein promoter, e.g., a goat beta casein promoter, a milk-specific signal sequence, e.g., a casein signal sequence, e.g., a ⁇ -casein signal sequence, and a DNA encoding the heterologous protein.
- the construct can also include a 3' untranslated region downstream of the DNA sequence coding for the non-secreted protein. Such regions can stabilize the RNA transcript of the expression system and thus increases the yield of desired protein from the expression system.
- 3' untranslated regions useful in the constructs for use in the invention are sequences that provide a poly A signal. Such sequences may be derived, e.g., from the SV40 small t antigen, the casein 3' untranslated region or other 3' untranslated sequences well known in the art.
- the 3' untranslated region is derived from a milk specific protein. The length of the 3' untranslated region is not critical but the stabilizing effect of its poly A transcript appears important in stabilizing the RNA of the expression sequence.
- the construct can include a 5' untranslated region between the promoter and the DNA sequence encoding the signal sequence.
- Such untranslated regions can be from the same control region from which promoter is taken or can be from a different gene, e.g., they may be derived from other synthetic, semi-synthetic or natural sources. Again their specific length is not critical, however, they appear to be useful in improving the level of expression.
- the construct can also include about 10%o, 20%, 30%>, or more of the N-terminal coding region of a gene preferentially expressed in mammary epithelial cells.
- the N- terminal coding region can correspond to the promoter used, e.g., a goat ⁇ -casein N-terminal coding region.
- the construct can be prepared using methods known in the art.
- the construct can be prepared as part of a larger plasmid. Such preparation allows the cloning and selection of the correct constructions in an efficient manner.
- the construct can be located between convenient restriction sites on the plasmid so that they can be easily isolated from the remaining plasmid sequences for incorporation into the desired mammal.
- heterologous Target Proteins Transgenic sequences encoding heterologous target proteins can be introduced into the germline of a non-human mammal or can be transfected into a cell line as described above.
- the protein can be a complex or multimeric protein, e.g., a homo- or heteromultimer, e.g., proteins which naturally occur as homo- or heteromultimers, e.g., homo- or hetero- dimers, trimers or tetramers.
- the protein can be a protein which is processed by removal, e.g., cleavage, of N-terminus, C-terminus or internal fragments. Even complex proteins can be expressed in active form.
- Protein encoding sequences which can be introduced into the genome of mammal, e.g., bovines or goats include a serum protein, a milk protein, a glycosylated or a non- glycosylated protein.
- the protein may be human or non-human in origin.
- the heterologous protein may be a potential therapeutic or pharmaceutical agent such as, but not limited to: alpha- 1 proteinase inhibitor, alpha- 1 antitrypsine, alkaline phosphatase, angiogenin, antithrombin III, any of the blood clotting factors including Factor VIII, Factor IX, and Factor X, bone matrix protein (e.g., BMP 1-15), chitinase, erythropoietin, extracellular superoxide dismutase, fibrinogen, glucocerebrosidase, glutamate decarboxylase, human growth factor, human serum albumin, immunoglobulin, insulin, myelin basic protein, proinsulin, prolactin, soluble CD4 or a component or complex thereof, lactofemn, lactoglobulin, lysozyme, lactalbumin, transforming growth factor (TGF), e.g., TGF- ⁇ , tissue plasminogen activator or a variant thereof.
- Nucleotide sequence information is available for several of the genes encoding the heterologous proteins listed above, in at least one, and often in several organisms. See e.g., Long et al. (1984) Biochem. 23(21):4828-4837 (aplha-1 antitrypsin); Mitchell et al. (1986) Prot. Natl. Acad. Sci USA 83:7182-7186 (alkaline phosphatase); Schneider et al. (1988) EMBO J.
- a multivalent bmding polypeptide fusion protein can be prepared with standard recombinant DNA techniques using a nucleic acid molecule encoding the fusion protein.
- a nucleotide sequence encoding a fusion protein can be synthesized by standard DNA synthesis methods.
- a construct can be engineered to express an inactive protein using the mammalian tissue culture transient expression system.
- a gene construct can be ligated into a vector such as pcDNAIIl or pCEP4.
- the transfection can be carried out using standard techniques and representative samples of both supernatant and cell pellet can be obtained. Since the tissue culture system is relatively fast, the characteristics of the inactive protein can quickly be determined.
- an inactive protein can be secreted and that an active protein, e.g., BMP, can then be obtained using, for example, the tissue culture system, a construct which expresses an inactive protein can be placed into the cloning site of the mammary gland expression system such as a system which includes goat beta casein. These constructs can be used to generate transgenic mice. This allows for testing the expression of the protein into milk. In addition, the health of the mammary gland and the animal can be monitored.
- an active protein e.g., BMP
- the bioactivity of the expressed proteins can be monitored by the following methods. Since the proteins are inactive and then activated, testing of bioactivity of a protein can be performed. The bioactivity can be measured in a cell-based assay or in an in vivo model.
- a protein can be transgenically produced in an inactive form by modifying a site needed for activation of the protein, e.g., a cleavage site.
- a site needed for activation of the protein e.g., a cleavage site.
- proteins include the TGF- ⁇ family of molecules which are activated by cleavage during secretion.
- the cleavage site of such molecules can be modified such that cleavage does not occur during secretion.
- TGF- ⁇ was produced in which the KKRK cleavage site was replaced with the chymosin 10 amino acid recognition sequence.
- the protein was secreted undipped and then processed in the test tube with the chymosin enzyme to yield the activated protein.
- proinsulin Preferably, enzymatic cleavages are used that can function on the already folded molecules and which have the ability to follow the activity of the protein.
- An activation site of BMP-2 can also be modified such that cleavage does not occur during secretion of BMP-2 and it is secreted in its pro form.
- the pro-form can be cleaved following purification.
- An activation site of BMP-2 has the following sequence: RKRLK. This sequence can be modified to provide a different cleavage site which is not cleaved during secretion of BMP-2, but can be cleaved after secretion using a proteolytic enzyme which is not normally expressed in the specific tissue or product.
- exogenous proteolytic sites can be tried to obtain an inactive protein. These include sites for cleavage by acid, cyanogen bromide, Factor X, or chymosin. By analyzing the protein sequence, the potential sites can be designed. Various versions of a protein such as BMP with new cleavage sites can be constructed and run them through the tissue culture system. In addition, the protein can be tested to determine whether it is secreted in an inactive pro-form. Both culture supernatant and cell pellets can be tested for the levels of the protein. The pro- forms can also be tested to show that they have no biological activity. If the inactive protein is expressed in the mammary gland, it is preferable that the additional cleavage site is not cleaved by serum proteases since the milk has serum proteins in it at a low level.
- the additional site is cleaved such that the protein includes less than 20, 10, 5, 4, 3, 2, 1, or no extraneous amino acid residues.
- a site must be designed so that only the BMP sequence is present following cleavage.
- the success of the cleavage step can be monitored by Western analysis.
- an antibody capable or recognizing the activated protein such as active BMP is used.
- an assay can be done for bioactivity. It will be important to run wild-type active protein through the whole system to insure that there is no inactivation is taking place. Also, testing the unprocessed protein for activity can be done.
- the constructs can then be tested in the mouse milk system. The activation of the protein can also be tested when it is mixed with mouse and goat milk.
- Transgenic mice can be used to test the ability to secrete a protein in proform.
- modified BMP-2 DNA can be ligated into a goat beta casein expression vector.
- the DNA can be used to generate transgenic mice that should produce the protein in their milk.
- control mice can be used which express wild-type BMP-2.
- Milk can be obtained from representative lines, as well as biopsies for Northern analysis.
- the milk and tissue samples can be tested for expression of the BMP-2 proteins by Western analysis. Specifically, production of the active protein in milk can be tested using the appropriate cleavage enzymes. The activation can be monitored as was done with the tissue culture expression experiments.
- a protein can be transgenically produced in an inactive form by co expression of the protein with a binding protein which binds to and inactivates the protein.
- a protein and binding protein can be a receptor and ligand, or fragments or either.
- the bmding protein can also be an antibody.
- a protein can be expressed as a fusion protein with the binding protein.
- BMP protein can be expressed as a fusion protein with its own receptor. The assumption is that the receptor will bind to BMP and prevent it from interacting with the receptor in the mammary gland or in the animal.
- the receptor can be linked to the BMP through a cleavable linker. Once the inactive version is produced, the linker can be cleaved, allowing the receptor and BMP to dissociate and thereby activating the BMP molecule.
- the cleavable linker is not recognized by an endogenous processing enzyme which naturally occurs in the tissue or product from the transgenic animal, but is recognized by processing enzymes in a subject who is administered the inactive polypeptide.
- the inactive polypeptide can be administered to a subject, e.g., a human, such that processing enzymes present in the subject can cleave the binding polypeptide from the target polypeptide thereby activating the target polypeptide.
- a binding protein/protein fusions can be tested for expression, for example, in COS cells. Expression can be tested by analysis with monoclonal antibody directed to either the protein or the binding protein, e.g., either BMP or its receptor. The fusion protein can also be tested for activity.
- the fusion protein can be cleaved with the appropriate enzyme and cleavage can be monitored by Western blot. The expectation is that the fusion protein will be inactive until cleaved by the protease.
- a fusion protein which includes a protein and a binding protein can also be tested for its expression in milk.
- the fusion construct can be ligated, for example, into the beta casein expression vector.
- the vector can then be used to generate transgenic mice. These mice can be tested for their ability to express the protein.
- the animals can be tested for the effect of the protein on the mammary gland and the animal in general.
- BMP and an antibody against BMP can be used to produce inactive BMP.
- An antibody of interest can be expressed in COS cells along with the protein such as BMP. The effect of the antibody on BMP activity can then be monitored.
- An active protein such as active BMP can be obtained following expression with an antibody using, for example, Protein A to selectively bind the antibody portion of the protein/antibody complex.
- the binding protein can further include at least one amino acid which is exogenous to the binding protein.
- a BMP receptor can further include an exogenous amino acid sequence which is useful for purification of the binding protein and/or the binding protein/protein complex.
- the additional amino acid sequence can be use to bind to a preselected ligand such as a 6X HIS ligand, a cellulose binding domain ligand, or a maltose binding domain ligand.
- binding proteins can be tested for their ability to bind and inhibit a protein.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15974899P | 1999-10-14 | 1999-10-14 | |
US159748P | 1999-10-14 | ||
US20466200P | 2000-05-17 | 2000-05-17 | |
US204662P | 2000-05-17 | ||
PCT/US2000/028589 WO2001026455A1 (fr) | 1999-10-14 | 2000-10-16 | Methodes de production d'une molecule cible chez un animal transgenique et de purification de la molecule cible |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1220606A1 true EP1220606A1 (fr) | 2002-07-10 |
EP1220606A4 EP1220606A4 (fr) | 2004-04-14 |
Family
ID=26856252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00970945A Withdrawn EP1220606A4 (fr) | 1999-10-14 | 2000-10-16 | Methodes de production d'une molecule cible chez un animal transgenique et de purification de la molecule cible |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1220606A4 (fr) |
JP (1) | JP2003511048A (fr) |
KR (1) | KR100772465B1 (fr) |
CN (1) | CN1322003C (fr) |
AU (1) | AU781944B2 (fr) |
BR (1) | BR0014860A (fr) |
CA (1) | CA2382741A1 (fr) |
HU (1) | HUP0203537A2 (fr) |
IL (1) | IL149003A0 (fr) |
MX (1) | MXPA02003702A (fr) |
NO (1) | NO20021686L (fr) |
NZ (1) | NZ518263A (fr) |
RU (1) | RU2002112460A (fr) |
WO (1) | WO2001026455A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030049694A1 (en) * | 2001-09-10 | 2003-03-13 | Chung-Hsiun Wu | Production of fusion proteins and use for identifying binding molecules |
US6800462B2 (en) * | 2001-09-10 | 2004-10-05 | Abgenomics Corporation | Production of recombinant proteins in vivo and use for generating antibodies |
CN1283785C (zh) * | 2002-05-20 | 2006-11-08 | 上海杰隆生物工程股份有限公司 | 利用转基因动物乳腺生产人促红细胞生成素的方法 |
WO2007052096A2 (fr) * | 2005-06-29 | 2007-05-10 | Cameron Malcolm Lang Clokie | Production de proteines morphogeniques osseuses dans des mammiferes transgeniques |
CA2690564A1 (fr) * | 2007-06-13 | 2008-12-24 | Sterrenbeld Biotechnologie North America, Inc. | Procede de creation de mammiferes transgeniques qui produisent des proteines exogenes dans leur lait et mammiferes transgeniques ainsi crees |
US9150880B2 (en) | 2008-09-25 | 2015-10-06 | Proteovec Holding, L.L.C. | Vectors for production of antibodies |
US9157097B2 (en) | 2008-09-25 | 2015-10-13 | Proteovec Holding, L.L.C. | Vectors for production of growth hormone |
WO2010118360A1 (fr) | 2009-04-09 | 2010-10-14 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Production de protéines au moyen de vecteurs à base de transposon |
EP2793936A4 (fr) * | 2011-12-19 | 2015-05-27 | Lfb Usa Inc | Alpha-1-antitrypsine humaine recombinante pour le traitement de troubles inflammatoires |
AR094778A1 (es) | 2013-02-13 | 2015-08-26 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteínas con glicosilación modificada y métodos para producirlas |
KR20160002713A (ko) | 2013-02-13 | 2016-01-08 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도 |
JP2016532100A (ja) | 2013-07-05 | 2016-10-13 | ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーLaboratoire Francais Du Fractionnement Et Des Biotechnologies | アフィニティークロマトグラフィーマトリックス |
FR3025515B1 (fr) | 2014-09-05 | 2016-09-09 | Lab Francais Du Fractionnement | Procede de purification d'un anticorps monoclonal |
FR3034420A1 (fr) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
JP6712125B2 (ja) * | 2015-09-04 | 2020-06-17 | 株式会社フジクラ | 酸化物超電導線材の接続構造体およびその製造方法 |
FR3060394B1 (fr) | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-amhrii |
FR3060395B1 (fr) | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-her2 |
FR3076294B1 (fr) | 2017-12-29 | 2022-01-28 | Lab Francais Du Fractionnement | Procede de purification d'anticorps a partir de lait brut |
WO2023118241A1 (fr) | 2021-12-20 | 2023-06-29 | Vetoquinol Sa | Anticorps anti-récepteur a de l'interleukine-31 canin (il-31ra) et leurs utilisations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007428A1 (fr) * | 1989-11-20 | 1991-05-30 | Novo Nordisk A/S | Procede de purification de proteines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639940A (en) * | 1994-03-03 | 1997-06-17 | Pharmaceutical Proteins Ltd. | Production of fibrinogen in transgenic animals |
CN1114357A (zh) * | 1994-07-01 | 1996-01-03 | 唐勇炜 | 利用转基因动物生产重组多肽 |
-
2000
- 2000-10-16 KR KR1020027004804A patent/KR100772465B1/ko not_active IP Right Cessation
- 2000-10-16 HU HU0203537A patent/HUP0203537A2/hu unknown
- 2000-10-16 RU RU2002112460/13A patent/RU2002112460A/ru unknown
- 2000-10-16 NZ NZ518263A patent/NZ518263A/en unknown
- 2000-10-16 AU AU80254/00A patent/AU781944B2/en not_active Ceased
- 2000-10-16 JP JP2001529255A patent/JP2003511048A/ja active Pending
- 2000-10-16 WO PCT/US2000/028589 patent/WO2001026455A1/fr active IP Right Grant
- 2000-10-16 BR BR0014860-1A patent/BR0014860A/pt not_active Application Discontinuation
- 2000-10-16 CA CA002382741A patent/CA2382741A1/fr not_active Abandoned
- 2000-10-16 IL IL14900300A patent/IL149003A0/xx unknown
- 2000-10-16 MX MXPA02003702A patent/MXPA02003702A/es not_active Application Discontinuation
- 2000-10-16 EP EP00970945A patent/EP1220606A4/fr not_active Withdrawn
- 2000-10-16 CN CNB008152802A patent/CN1322003C/zh not_active Expired - Fee Related
-
2002
- 2002-04-10 NO NO20021686A patent/NO20021686L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007428A1 (fr) * | 1989-11-20 | 1991-05-30 | Novo Nordisk A/S | Procede de purification de proteines |
Non-Patent Citations (1)
Title |
---|
See also references of WO0126455A1 * |
Also Published As
Publication number | Publication date |
---|---|
NO20021686L (no) | 2002-06-12 |
RU2002112460A (ru) | 2004-02-27 |
AU781944B2 (en) | 2005-06-23 |
NZ518263A (en) | 2004-03-26 |
AU8025400A (en) | 2001-04-23 |
CN1322003C (zh) | 2007-06-20 |
NO20021686D0 (no) | 2002-04-10 |
CN1387399A (zh) | 2002-12-25 |
MXPA02003702A (es) | 2002-09-18 |
WO2001026455A1 (fr) | 2001-04-19 |
EP1220606A4 (fr) | 2004-04-14 |
IL149003A0 (en) | 2002-11-10 |
BR0014860A (pt) | 2003-07-08 |
HUP0203537A2 (hu) | 2003-02-28 |
KR100772465B1 (ko) | 2007-11-02 |
CA2382741A1 (fr) | 2001-04-19 |
JP2003511048A (ja) | 2003-03-25 |
KR20030022759A (ko) | 2003-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU781944B2 (en) | Methods of producing a target molecule in a transgenic animal and purification of the target molecule | |
US20040226053A1 (en) | Methods of producing a target molecule in a transgenic animal and purification of the target molecule | |
NZ278744A (en) | Transgenic production of immunoglobulin in milk and transgenic animals selectively expressing the gene for the antibody | |
US20060179500A1 (en) | Methods and vectors for improving nucleic acid expression | |
US20040092719A1 (en) | Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds | |
WO2000026357A2 (fr) | Mammiferes transgeniques et clones | |
US20030177513A1 (en) | Transgenic and cloned mammals | |
AU781915B2 (en) | Method of purifying heterologous proteins | |
AU8025400B2 (fr) | ||
US20030046716A1 (en) | Transgenically produced platelet derived growth factor | |
US20050193431A1 (en) | Somatic cell line | |
EP1375654A2 (fr) | Mammifères trangéniques et clonés | |
EP1194033B1 (fr) | Antithrombine iii produite de maniere transgenique et mutants de celle-ci | |
AU1492801A (en) | Methods of producing cloned and transgenic mammals | |
AU2003204830B2 (en) | Transgenic and cloned mammals | |
AU2004210607A1 (en) | Transgenic and cloned mammals | |
AU2008202456A1 (en) | Transgenic and cloned mammals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020404 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GTC BIOTHERAPEUTICS, INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040226 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07K 1/22 B Ipc: 7C 07K 1/00 B Ipc: 7C 12N 15/62 B Ipc: 7A 01K 67/00 A Ipc: 7C 12P 21/00 B Ipc: 7A 01K 67/027 B |
|
17Q | First examination report despatched |
Effective date: 20050203 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080424 |